Acute Bacterial Skin and Skin Structure Infections Market Report 2026

The acute bacterial skin and skin structure infections market size has grown strongly in recent years. It will grow from $12.9 billion in 2025 to $14.09 billion in 2026 at a compound annual growth rate (CAGR) of 9.2%. The growth in the historic period can be attributed to limited availability of broad-spectrum antibiotics, rising prevalence of hospital-acquired infections, increasing awareness of skin infection complications, growth in community healthcare access, adoption of standard infection control protocols.

The acute bacterial skin and skin structure infections market size is expected to see rapid growth in the next few years. It will grow to $20.79 billion in 2030 at a compound annual growth rate (CAGR) of 10.2%. The growth in the forecast period can be attributed to development of next-generation antibiotics, increasing investments in antimicrobial research, growing community-based infection management programs, expansion of hospital pharmacy distribution channels, implementation of rapid diagnostic technologies. Major trends in the forecast period include rising incidence of acute bacterial skin and skin structure infections, growing adoption of novel antibiotics and combination therapies, expansion of hospital and community healthcare facilities, increasing use of oral and parenteral antibiotics, focus on reducing hospital-acquired infection rates.

The rising prevalence of skin infections is expected to drive the growth of the acute bacterial skin and skin structure infections market going forward. Skin infections occur when microorganisms, such as bacteria, fungi, or viruses, invade and multiply within the skin, causing various symptoms and discomfort. The increase in skin infections fuels demand for therapeutic solutions, antibiotics, and innovative treatments to manage acute bacterial and skin structure infections, ensuring patients receive effective care and improved outcomes. For instance, in March 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, approximately 1.8 billion people globally are affected by skin conditions at any given time. Neglected tropical diseases (NTDs) account for around 10% of these cases, with fungal infections at 34% and bacterial infections at 23%, often resulting in high mortality rates. Therefore, the rising prevalence of skin infections is driving the growth of the acute bacterial skin and skin structure infections market.

Major companies operating in the acute bacterial skin and skin structure infections market are developing innovative single-dose therapies, such as Dalbonova, to strengthen their market position. Dalbonova is a single-dose therapy designed for convenience and effectiveness, allowing patients to achieve results with a single 1500 mg dose. For instance, in August 2023, BDR Pharmaceuticals International Pvt. Ltd., an India-based pharmaceutical company specializing in APIs and therapeutic formulations, launched Dalbonova injection, a single-dose treatment for acute bacterial skin and skin structure infections (ABSSSI). Dalbonova injection helps reduce the risk of hospital-acquired infections by eliminating the need for hospital admissions and is indicated for treating ABSSSI caused by certain gram-positive microorganisms in patients of all ages, including newborns.

In July 2023, Melinta Therapeutics, a US-based pharmaceutical company, partnered with the Biomedical Advanced Research and Development Authority to advance two FDA-approved antibiotics, Baxdela and Minocin, for pediatric use. Through this collaboration, Merck aims to strengthen its haematology pipeline by leveraging Imago BioSciences' innovative therapies for myeloproliferative neoplasms and other bone marrow disorders, expanding its ability to deliver breakthrough treatments to patients with severe conditions. The Biomedical Advanced Research and Development Authority is a US-based government agency focused on developing and acquiring medical countermeasures to protect the United States from public health threats.

Major companies operating in the acute bacterial skin and skin structure infections market are Pfizer Inc., AbbVie Inc., Novartis AG, GSK PLC, Takeda Pharmaceutical Company Limited, Viatris Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Limited, Dr. Reddy's Laboratories Ltd., Cipla Limited, Lupin Limited, Zydus Lifesciences Limited, Aurobindo Pharma Limited, Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, Aspen Pharmacare Holdings Limited, Melinta Therapeutics LLC, Abbott Laboratories, Fresenius SE & Co. KGaA, Menarini Group.

Asia-Pacific was the largest region in the acute bacterial skin and skin structure infections market in 2025. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the acute bacterial skin and skin structure infections market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the acute bacterial skin and skin structure infections market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the acute bacterial skin and skin structure infections market by increasing the cost of imported antibiotics, active pharmaceutical ingredients, and medical supplies. Segments such as parenteral and oral antibiotic formulations are most affected, particularly in regions like north america, europe, and asia-pacific with high import dependency. These tariffs have led to higher treatment costs and supply chain delays. On the positive side, tariffs have encouraged local production of antibiotics and strengthened domestic pharmaceutical manufacturing capabilities.

The acute bacterial skin and skin structure infections market research report is one of a series of new reports that provides acute bacterial skin and skin structure infections market statistics, including acute bacterial skin and skin structure infections industry global market size, regional shares, competitors with a acute bacterial skin and skin structure infections market share, detailed acute bacterial skin and skin structure infections market segments, market trends and opportunities, and any further data you may need to thrive in the acute bacterial skin and skin structure infections industry. This acute bacterial skin and skin structure infections market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Acute bacterial skin and skin structure infections (ABSSSIs) are bacterial infections that affect the skin and underlying tissues, causing symptoms such as redness, swelling, pain, and warmth in the affected area. Medical interventions, including antibiotic treatments, are used to prevent complications and promote healing in infections ranging from mild to severe.

The main types of acute bacterial skin and skin structure infections are hospital-acquired ABSSSIs and community-acquired ABSSSIs. Hospital-acquired ABSSSIs are infections of the skin and underlying tissues that develop as a result of medical care or hospitalization. Common active ingredients used in treatment include delafloxacin, vancomycin, ceftaroline fosamil, oritavancin, tedizolid, daptomycin, tigecycline, linezolid, and others, which can be administered via oral, parenteral, or topical routes. These treatments are distributed through hospital pharmacies, retail pharmacies, and online pharmacies and are used for applications such as cellulitis, abscesses, surgical wounds, and traumatic wounds.

The acute bacterial skin and skin structure infections market consists of revenues earned by entities by providing services such as diagnostic testing, surgical procedures for abscess drainage or debridement, inpatient and outpatient healthcare services, and home healthcare and wound care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The acute bacterial skin and skin structure infections market also includes sales of wound dressings and bandages, medical devices for wound care, vaccines, hydrogen peroxide, and fusidic acid. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.